Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets

Neuropharmacology

Volumn 52, Issue 4, 2007, Pages 1095-1105

  Zhang, Di ^a   Saraf, Anita ^a   Kolasa, Teodozyi ^a   Bhatia, Pramila ^a   Zheng, Guo Zhu ^a   Patel, Meena ^a   Lannoye, Greg S ^a   Richardson, Paul ^a   Stewart, Andrew ^a   Rogers, John C ^a   Brioni, Jorge D ^a   Surowy, Carol S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABPP; Carboxylesterase; FAAH; Inhibitor; MudPIT

Indexed keywords

5 (4 FLUOROBENZYL) N,N DIMETHYL 1H TETRAZOLE 1 CARBOXAMIDE; 7 PHENYL 1 (5 PYRIDIN 2 YL OXAZOL 2 YL)HEPTAN 1 ONE; [2 (6' METHYL 3,4,5,6 TETRAHYDRO 2H [1,2']BIPYRIDINYL 4 YL)ETHYL]CARBAMIC ACID METHYLCARBAMOYLMETHYL ESTER; [3 [5 (6 METHOXYNAPHTHALEN 1 YL)[1,4]DIOXAN 2 YL]PROPYL]CARBAMIC ACID CARBAMOYLMETHYL ESTER; [6 (2 METHYL 4,5 DIPHENYLIMIDAZOL 1 YL)HEXYL]CARBAMIC ACID 2 FLUOROPHENYL ESTER; ANANDAMIDE; BMS 1; CARBAMIC ACID DERIVATIVE; CARBOXYLESTERASE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; ISOENZYME; LY 2077855; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; OL 135; SA 47; SA 72; SERINE DEHYDRATASE; UNCLASSIFIED DRUG;

ACTIVITY BASED PROTEIN PROFILING; ANIMAL TISSUE; ANXIETY; ARTICLE; DEPRESSION; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; PROTEOMICS; RAT;

AMIDOHYDROLASES; ANIMALS; ANTIBODIES; BENZAMIDES; BRAIN; CARBAMATES; CARBOXYLESTERASE; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; HEART; HUMANS; KIDNEY; LIVER; PROTEOME; RATS; TRANSFECTION;

EID: 33847283286     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.11.009     Document Type: Article

References (47)

1. Abouabdellah, A., Bas, M., Dargazanli, G., Hoornaert, C., Li, A.T., Medaisko, F., 2005. Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics. Patent US20050182130 A1.
2. Abouabdellah, A., Burnier, P., Hoornaert, C., Jeunesse, J., Puech, F., 2006. Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of some in therapeutics. Patent US20060089344 A1.
3. Alexander J.P., and Cravatt B.F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol. 12 (2005) 1179-1187
4. Alexander J.P., and Cravatt B.F. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J. Am. Chem. Soc. 128 (2006) 9699-9704
5. Batkai S., Pacher P., Osei-Hyiaman D., Radaeva S., Liu J., Harvey-White J., Offertaler L., Mackie K., Rudd M.A., Bukoski R.D., and Kunos G. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110 (2004) 1996-2002
6. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
7. Boger, D.L., 2004. Inhibitors of fatty acid amide hydrolase. Patent WO2004033652 A2.
8. Boger D.L., Miyauchi H., Du W., Hardouin C., Fecik R.A., Cheng H., Hwang I., Hedrick M.P., Leung D., Acevedo O., Guimaraes C.R., Jorgensen W.L., and Cravatt B.F. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem. 48 (2005) 1849-1856
9. Boger D.L., Sato H., Lerner A.E., Hedrick M.P., Fecik R.A., Miyauchi H., Wilkie G.D., Austin B.J., Patricelli M.P., and Cravatt B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5044-5049
10. Bracey M.H., Hanson M.A., Masuda K.R., Stevens R.C., and Cravatt B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298 (2002) 1793-1796
11. Calignano A., La Rana G., Beltramo M., Makriyannis A., and Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337 (1997) R1-R2
12. Chang L., Luo L., Palmer J.A., Sutton S., Wilson S.J., Barbier A.J., Breitenbucher J.G., Chaplan S.R., and Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148 (2006) 102-113
13. Clapper J.R., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol. Res. 54 (2006) 341-344
14. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9371-9376
15. Cravatt B.F., and Lichtman A.H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 7 (2003) 469-475
16. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 377-391
17. Dolinsky V.W., Gilham D., Alam M., Vance D.E., and Lehner R. Triacylglycerol hydrolase: role in intracellular lipid metabolism. Cell. Mol. Life Sci. 61 (2004) 1633-1651
18. Furihata T., Hosokawa M., Fujii A., Derbel M., Satoh T., and Chiba K. Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma. Biochem. Pharmacol. 69 (2005) 1287-1297
19. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., and Deutsch D.G. Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4269-4274
20. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 18620-18625
21. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146 (2005) 467-476
22. Jessani N., Niessen S., Wei B.Q., Nicolau M., Humphrey M., Ji Y., Han W., Noh D.Y., Yates III J.R., Jeffrey S.S., and Cravatt B.F. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2 (2005) 691-697
23. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
24. Kidd D., Liu Y., and Cravatt B.F. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40 (2001) 4005-4015
25. Leung D., Du W., Hardouin C., Cheng H., Hwang I., Cravatt B.F., and Boger D.L. Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg. Med. Chem. Lett. 15 (2005) 1423-1428
26. Leung D., Hardouin C., Boger D.L., and Cravatt B.F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21 (2003) 687-691
27. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311 (2004) 441-448
28. Liederer B.M., and Borchardt R.T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95 (2006) 1177-1195
29. Linke T., Dawson H., and Harrison E.H. Isolation and characterization of a microsomal acid retinyl ester hydrolase. J. Biol. Chem. 280 (2005) 23287-23294
30. Liu Y., Patricelli M.P., and Cravatt B.F. Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14694-14699
31. Lodola A., Mor M., Hermann J.C., Tarzia G., Piomelli D., and Mulholland A.J. QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem. Commun. (Camb.) (2005) 4399-4401
32. Massa F., Marsicano G., Hermann H., Cannich A., Monory K., Cravatt B.F., Ferri G.L., Sibaev A., Storr M., and Lutz B. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113 (2004) 1202-1209
33. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
34. Moore S.A., Nomikos G.G., Dickason-Chesterfield A.K., Schober D.A., Schaus J.M., Ying B.P., Xu Y.C., Phebus L., Simmons R.M., Li D., Iyengar S., and Felder C.C. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17852-17857
35. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., Tontini A., Piersanti G., Kathuria S., and Piomelli D. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 47 (2004) 4998-5008
36. Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Liu J., Harvey-White J., Brassai A., Jarai Z., Cravatt B.F., and Kunos G. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H533-H541
37. Patricelli M.P., Giang D.K., Stamp L.M., and Burbaum J.J. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1 (2001) 1067-1071
38. Perra S., Pillolla G., Melis M., Muntoni A.L., Gessa G.L., and Pistis M. Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. Psychopharmacology (Berl.) (2005) 1-10
39. Porter A.C., Li J., Love P.L., Shannon H.E., Li D.L., Phebus L.A., Gleason S.D., Witkin J.M., Simmons R.M.A., Iyengar S., and Nomikos G.G. LY2077855: a novel, potent, selective, non-endocannabinoid related inhibitor of anandamide inactivation demonstrates robust analgesic effects in an in vivo pain model. Soc. Neurosci. (2004) (Program No. 273.11)
40. Quinney S.K., Sanghani S.P., Davis W.I., Hurley T.D., Sun Z., Murry D.J., and Bosron W.F. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J. Pharmacol. Exp. Ther. 313 (2005) 1011-1016
41. Sanghani S.P., Davis W.I., Dumaual N.G., Mahrenholz A., and Bosron W.F. Identification of microsomal rat liver carboxylesterases and their activity with retinyl palmitate. Eur. J. Biochem. 269 (2002) 4387-4398
42. Satoh T., and Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 257-288
43. Sit, S.Y., Xie, K., 2002. Bisarylimidazolyl fatty acid amide hydrolase inhibitors. Patent US 6562846 B2.
44. Wadkins R.M., Hyatt J.L., Wei X., Yoon K.J., Wierdl M., Edwards C.C., Morton C.L., Obenauer J.C., Damodaran K., Beroza P., Danks M.K., and Potter P.M. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J. Med. Chem. 48 (2005) 2906-2915
45. Wadkins R.M., Hyatt J.L., Yoon K.J., Morton C.L., Lee R.E., Damodaran K., Beroza P., Danks M.K., and Potter P.M. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol. Pharmacol. 65 (2004) 1336-1343
46. Wheelock C.E., Severson T.F., and Hammock B.D. Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility. Chem. Res. Toxicol. 14 (2001) 1563-1572
47. Zhang D., Chen J., Saraf A., Cassar S., Han P., Rogers J.C., Brioni J.D., Sullivan J.P., and Gopalakrishnan M. Association of catsper1 or -2 with Cav3.3 leads to suppression of T-type calcium channel activity. J. Biol. Chem. 281 (2006) 22332-22341